Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Purchases Another $35 Million of Simcere’s Stock

publication date: Mar 23, 2012
Fosun Pharma has bought another slice of Simcere Pharma, paying $35 million on the open market for slightly less than a 1% stake. The latest purchase brings their holdings to 7.5% of the company’s outstanding shares. Fosun, which has been nibbling at Simcere for some time now, has not declared any desire to acquire Simcere, but it seems only reasonable that they will eventually seek some sort of relationship. More details....

Stock Symbols: (SHE: 600196) (NYSE: SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital